Lorazepam
- Generic Name
- Lorazepam
- Brand Names
- Ativan, Loreev
- Drug Type
- Small Molecule
- Chemical Formula
- C15H10Cl2N2O2
- CAS Number
- 846-49-1
- Unique Ingredient Identifier
- O26FZP769L
- Background
Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.
- Indication
Lorazepam is FDA-approved for the short-term relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxiety-associated insomnia. It is as well used as an anesthesia premedication in adults to relieve anxiety or to produce sedation/amnesia and for the treatment of status epilepticus.
...
- Associated Conditions
- Agitation, Alcohol Withdrawal Delirium, Alcohol Withdrawal Syndrome, Anxiety, Anxiety Disorders, Chemotherapy-Induced Nausea and Vomiting, Delirium, Insomnia, Muscle Spasms, Panic Disorder, Psychogenic Catatonia, Status Epilepticus
- Associated Therapies
- Anesthetic premedication therapy
Dextromethorphan to Treat Patients With Voice Spasms
- Conditions
- First Posted Date
- 2003-03-05
- Last Posted Date
- 2017-07-02
- Target Recruit Count
- 65
- Registration Number
- NCT00055549
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Lorazepam-Induced Toxicity in the Aged
- Conditions
- First Posted Date
- 2002-09-05
- Last Posted Date
- 2013-12-06
- Lead Sponsor
- Nathan Kline Institute for Psychiatric Research
- Target Recruit Count
- 90
- Registration Number
- NCT00044642
- Locations
- 🇺🇸
NYU/Bellevue General Clinical Research Center (8East), New York, New York, United States
🇺🇸Nathan S. Kline Institute, Orangeburg, New York, United States
Phase III Randomized Study of Diazepam Vs Lorazepam Vs Placebo for Prehospital Treatment of Status Epilepticus
- Conditions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2005-06-24
- Target Recruit Count
- 210
- Registration Number
- NCT00004297
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.